Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelinrelated peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 9, 2013, Pages 1815-1824

  Bandiera, Elisabetta ^a   Zanotti, Laura ^a   Fabricio, Aline S C ^b   Bucca, Elisa ^b   Squarcina, Elisa ^c   Romani, Chiara ^a   Tassi, Renata ^a   Bignotti, Eliana ^a   Todeschini, Paola ^a   Tognon, Germana ^a   Romagnolo, Cesare ^d   Gion, Massimo ^b   Sartori, Enrico ^a   Maggino, Tiziano ^e   Pecorelli, Sergio ^a   Ravaggi, Antonella ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Centro Regionale Biomarcatori   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d G Fracastoro Hospital   (Italy)

^e OSPEDALE DELL'ANGELO   (Italy)

Author keywords

Biomarkers; Diagnosis; Epithelial ovarian cancer; IgM

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; IMMUNOGLOBULIN M; KALLIKREIN 6; MESOTHELIN; OSTEOPONTIN;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; ASCITES; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; NORMAL HUMAN; OVARY CARCINOMA; OVARY CYST; PLASMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GPI-LINKED PROTEINS; HUMANS; IMMUNOASSAY; IMMUNOCONJUGATES; IMMUNOGLOBULIN M; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OSTEOPONTIN; OVARIAN NEOPLASMS; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888097593     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0151     Document Type: Article

References (44)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61: 212-36.
2. Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer. Clin Chim Acta 2013;415: 341-5.
3. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97: 922-9. (Pubitemid 20340625)
4. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, et al. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23: 7919-26. (Pubitemid 46657391)
5. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15: 274-81. (Pubitemid 43096594)
6. Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 2007;174: 91-100.
7. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. J Am Med Assoc 2011;305: 2295-303.
8. Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC Jr. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 2012;118: 91-100.
9. Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012;22(Suppl 1):S5-8.
10. Yip P, Chen TH, Seshaiah P, Stephen LL, Michael-Ballard KL, Mapes JP, et al. Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One 2011;6:e29533.
11. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, et al. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol 2011;122: 548-53.
12. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer PLCO Project Team. Cancer Prev Res 2011;4: 375-83.
13. Cramer DW, Bast RC Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011;4: 365-74.
14. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28: 2159-66.
15. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 2010;136: 1079-88.
16. Amonkar SD, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Seshaiah P, et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 2009;4:e4599.
17. Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2008;17: 2872-81.
18. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008;14: 1065-72. (Pubitemid 351302552)
19. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008;110: 374-82.
20. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 2007;107: 526-31. (Pubitemid 350160868)
21. Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004;22: 4059-66. (Pubitemid 41185174)
22. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108: 402-8. (Pubitemid 351174295)
23. Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev 2011;20: 2496-506.
24. Taylor DD, Gercel-Taylor C, Parker LP. Patient-derived tumorreactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 2009;115: 112-20.
25. Szubert S, Michalak S, Szpurek D, Moszynski R, Krygowska-Zielinska J, Sajdak S. Anti-ovarian antibodies in sera of patients with ovarian tumors. Immunol Lett 2012;148: 133-7.
26. Anderson KS, Wong J, Vitonis A, Crum CP, Sluss PM, Labaer J, et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 2010;193: 859-68.
27. Cramer DW, O'Rourke DJ, Vitonis AF, Matulonis UA, Dijohnson DA, Sluss PM, et al. CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem 2010;56: 1889-92.
28. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008;14: 764-71. (Pubitemid 351231158)
29. Nesterova M, Johnson N, Cheadle C, Cho-Chung YS. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006;1762: 398-403. (Pubitemid 43344300)
30. Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006;102: 244-51. (Pubitemid 44041638)
31. Barua A, Bradaric MJ, Kebede T, Espionosa S, Edassery SL, Bitterman P, et al. Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer. Am J Reprod Immunol 2007;57: 243-9. (Pubitemid 46394836)
32. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44: 837-45.
33. Castaldi F, Marino M, Beneduce L, Belluco C, De Marchi F, Mammano E, et al. Detection of circulating CEA-IgM complexes in early stage colorectal cancer. Int J Biol Markers 2005;20: 204-8. (Pubitemid 43103615)
34. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L, et al. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer 2005;103: 2558-65. (Pubitemid 40800535)
35. Pontisso P, Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, et al. Progressive increase of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. Int J Cancer 2006;119: 735-40. (Pubitemid 44051434)
36. Beneduce L, Prayer-Galetti T, Giustinian AM, Gallotta A, Betto G, Pagano F, et al. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients. Cancer Detect Prev 2007;31: 402-7. (Pubitemid 350166795)
37. Beneduce L, Pesce G, Gallotta A, Zampieri F, Biasiolo A, Tono N, et al. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. Eur J Clin Invest 2008; 38: 571-7. (Pubitemid 352019141)
38. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21: 137-48. (Pubitemid 39094044)
39. Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, et al. Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. Int J Gynecol Cancer 2009;19: 1015-21.
40. Luborsky JL, Barua A, Shatavi SV, Kebede T, Abramowicz J, Rotmensch J. Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol 2005;54: 55-62. (Pubitemid 41087067)
41. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100: 1315-9.
42. Bordin L, Fiore C, Donà G, Andrisani A, Ambrosini G, Faggian D, et al. Evaluation of erythrocyte band 3 phosphotyrosine level, glutathione content, CA-125, and human epididymal secretory protein E4 as combined parameters in endometriosis. Fertil Steril 2010;94: 1616-21.
43. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011;49: 521-5.
44. Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol 2011;205:358.e1-6.